| Popis: |
The clinical development of Interleukin-2 has been possible because the advent of biotechnology has resulted in the availability of unrestricted quantities of recombinant Interleukin-2 (rIL-2). Since there is little or no precedence, the initial investigational criteria used were those established for the evaluation of conventional cancer drugs [1]; that is the identification and subsequent administration of the maximum tolerated dose, and the assessment of efficacy based on objective response rate. However, since rIL-2 is an immune stimulant, and has no direct action as an anti-tumour agent [2, 3], it does not make sense to evaluate the compound using standard oncological criteria. A more global concept of efficacy (objective response, quality of life, and survival) would seem to be more relevant [4]. |
